Global Refractory Angina Market: Gene-based Therapies Augur Well for Future, says TMR Research

The rising prevalence of heart diseases and growing awareness among the consumers are two primary drivers of the global refractory angina market, according to a recent report by TMR Research. The report, titled “Refractory Angina Market Revenue, Opportunity, Segment and Key Trends 2025,” contains quantitative and qualitative analysis of the market in its current scenario and estimates the future until 2025. The report analyzes all the factors that are anticipated to influence the demand as well as profiles a number of key players of the market in order to represent the competitive landscape.

According to the report, consumers are now more aware of the symptoms of refractory angina, which can cause pain in the back, shoulder, neck, arm, or jaws as a result of lack of oxygen-rich blood in the heart. With this factor, and the growing prevalence of heart diseases, the demand in the global refractory angina is expected to sustain over the course of next few years. In the U.S. alone, more than 50,000 patients are diagnosed with refractory angina every year. On the other hand, the report observes that most of the available therapies are failing to improve the overall quality of the patient’s life, which is spreading a negative sentiment among the end users. This factor is expected to hinder the market for refractory angina from attaining its true potential. The report also notes a trend, anticipating new opportunities to open for the players in this market via some of the gene-based therapies that are currently under trails and may see day of light in the near future.

Request a Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=38

The global refractory angina market can be segmented on the basis of pharmacological therapies, invasive therapies, and non-invasive non-pharmacological therapies. Drugs such as Nicorandil, Estrogen, Ivabradine, L-arginine, and Ranolazine fall under pharmacological treatment segment while based on non-invasive non-pharmacological treatment, the market can be segmented into Transcutaneous Electrical Nerve Stimulation (TENS) and enhanced external counterpulsation (EECP).

Geographically, North America and Europe are the most profitable regions for the players in the global refractory angina market, owing to robust healthcare infrastructure and reimbursement policies from the respective governments. However, several emerging economies in Asia Pacific are also turning it into a lucrative region, owing to improving healthcare facilities and growing culture of medical tourism.

Request for TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=38

Vasomedical, Inc, Neovasc Inc., Ark Therapeutics Group plc, Cryopraxis, and Saneron CCEL Therapeutics, Inc. are some of the prominent companies currently operating in the global refractory angina market. The market is heavily dependent on research and development of new therapies, especially gene-based therapies, and introduction of new efficient drugs and therapies is expected to determine the leading player in the years to come.

Read Complete Report @ https://www.tmrresearch.com/refractory-angina-market

About TMR Research

TMR Research is a premier provider of customized market research and consulting ser-vices to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

Rohit Bhisey
Head - Internet Marketing
Tel: +1-415-520-1050
Email: sales@tmrresearch.com

This release was published on openPR.